CalciMedica Inc (CALC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.30-3.70%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CALC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -85.4% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
CALC — CFO transition
Dated 2026-10-16
CFO — Stephen Bardin: The CFO resigned immediately to pursue another opportunity, representing a sudden loss of a key financial officer without a named successor.
Why it matters: FDA aligned on the trial design, but CalciMedica said it needs more funding to start. A launch would move Auxora toward its next test.
Supportive ifThe company names a funding source and announces that it has started enrolling patients in the Phase 2b trial.
Worry ifThe company reports no funding plan or trial start, or says the study is delayed or paused.
Why it matters: The CFO left without a named successor in the supplied event summary. A replacement would address a gap in financial leadership.
Supportive ifThe company names a new CFO in a filing or press release.
Worry ifThe company says the CFO job is still open, or another finance leader leaves.
Why it matters: CalciMedica reported $18.6 million in cash and said funds covered its plan into the second half of 2027. The next report can test that timeline.
Watch forOn November 11, the company reports cash and keeps its runway at least through the second half of 2027.
Also watch forThe company reports a shorter runway, new cash needs, or a delay to a planned study tied to funding.
Why it matters: An IND filing would let CalciMedica seek to test its oral candidate in people. The company says it is still doing preclinical work.
Supportive ifCalciMedica announces that it submitted the CM5480 IND to the FDA by mid-2027.
Worry ifThe company delays the IND past mid-2027 or reports that safety or other study work blocks filing.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$426 on $10,000 · ±4.3% | How much price usually moves either way. |
| Bad day | $1,112 loss on $10,000 · 11.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,697 loss on $10,000 · 97.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The Phase 1b study will test Auxora in people with PAH. Its results may guide further work on CalciMedica’s lung program.
Watch forThe company reports Phase 1b PAH results in mid-2027, with measured changes in lung blood flow or right-heart function.
Also watch forThe data show no measured gains in lung blood flow or right-heart function. Or the company delays the data past mid-2027.